Business Context and Reporting Period
This Form 6-K filing by Novo Nordisk A/S, dated July 20, 2026, reports on the company's ongoing share repurchase programme. Novo Nordisk is a leading global healthcare company headquartered in Denmark, employing approximately 68,800 people across 80 countries. The filing specifically details transactions executed under a programme initiated on May 6, 2026, which is part of a broader 12-month repurchase plan starting February 4, 2026.
Key Financial Metrics
The filing focuses on capital allocation via share buybacks rather than operational financial performance. Key metrics include:
- Total Repurchase Programme Cap: Up to DKK 15 billion for the 12-month period beginning February 4, 2026.
- Specific Programme Cap (May 6, 2026): Up to DKK 11,200,000,010.45.
- Total Shares Repurchased (since Feb 4, 2026): 24,959,179 B shares.
- Average Purchase Price (since Feb 4, 2026): DKK 274.58 per B share.
- Total Transaction Value (since Feb 4, 2026): DKK 6,853,177,389.
- Treasury Shares Held: 42,144,480 B shares (0.9% of share capital).
- Total Share Capital: 4,465,000,000 A and B shares (including treasury shares).
Material Changes and Recent Activity
Between July 13, 2026, and July 17, 2026, the company executed five transactions, purchasing 195,000 shares daily. The average purchase price during this specific week ranged from DKK 320.55 to DKK 333.59. As of July 17, 2026, the accumulated value of transactions under the May 6 programme reached DKK 3,053,177,399 for 10,200,000 shares. The filing does not provide comparative data for prior periods regarding revenue, profit, or cash flow.
Guidance, Outlook, and Risks
Management expects to continue repurchasing B shares up to the DKK 15 billion limit during the 12-month period starting February 4, 2026. The filing notes that the programme is conducted in accordance with the EU Market Abuse Regulation (MAR) and Safe Harbour Rules. No specific risks, contingencies, or unusual items regarding operational performance are disclosed in this document; the focus remains strictly on the execution of the capital return programme.
Investor Verification Checklist
- Verify the remaining capacity under the DKK 15 billion total programme (approximately DKK 8.15 billion remaining as of July 17, 2026).
- Confirm the current market price of B shares relative to the recent average purchase price of DKK 320–333.
- Review the full list of transaction details on novonordisk.com for granular execution data.
- Note that this filing does not contain updated revenue, earnings, or cash flow figures; refer to the most recent Form 20-F or quarterly reports for operational metrics.